FDA Clears More Tolerable Diroximel Fumarate (Vumerity) for MS FDA Clears More Tolerable Diroximel Fumarate (Vumerity) for MS

Diroximel fumarate showed better GI tolerability compared with dimethyl fumarate in patients with relapsing forms of multiple sclerosis in the EVOLVE-MS-2 phase 3 study.FDA Approvals

Source: Medscape Allergy Headlines - October 30, 2019 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Alert Source Type: news